SLE (Systemic Lupus) Clinical Trial
Official title:
Serum Autotaxin as a Potential Biomarker in Systemic Lupus Erythematosus Patients and Its Relation to Disease Activity.
- Estimation of the serum ATX level in SLE patients in comparison to healthy subjects. - Evaluation of the relation of serum ATX level with disease activity and different clinical manifestation in SLE patients
Status | Not yet recruiting |
Enrollment | 94 |
Est. completion date | October 2025 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients who will be diagnosed as SLE according to the 2012 systemic lupus international collaborating clinics (SLICC) criteria . - SLE Patients older than 18 years old. Exclusion Criteria: - SLE Patients younger than 18 years old. - Patients with other rheumatic diseases or overlap syndromes. - Patients with malignancy. - Patients with chronic hepatitis C. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6. — View Citation
Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91. — View Citation
Iwata Y, Kitajima S, Yamahana J, Shimomura S, Yoneda-Nakagawa S, Sakai N, Furuichi K, Ogura H, Sato K, Toyama T, Yamamura Y, Miyagawa T, Hara A, Shimizu M, Ohkawa R, Kurano M, Yatomi Y, Wada T. Higher serum levels of autotaxin and phosphatidylserine-speci — View Citation
Magkrioti C, Galaris A, Kanellopoulou P, Stylianaki EA, Kaffe E, Aidinis V. Autotaxin and chronic inflammatory diseases. J Autoimmun. 2019 Nov;104:102327. doi: 10.1016/j.jaut.2019.102327. Epub 2019 Aug 28. — View Citation
Masuda A, Nakamura K, Izutsu K, Igarashi K, Ohkawa R, Jona M, Higashi K, Yokota H, Okudaira S, Kishimoto T, Watanabe T, Koike Y, Ikeda H, Kozai Y, Kurokawa M, Aoki J, Yatomi Y. Serum autotaxin measurement in haematological malignancies: a promising marker — View Citation
Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth — View Citation
Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996 Mar;35(3):248-54. doi: 10.1093/rheumatology/35.3.24 — View Citation
Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol. 1989;44:93-151. doi: 10.1016/s0065-2776(08)60641-0. No abstract available. — View Citation
Tokuhara Y, Kurano M, Shimamoto S, Igarashi K, Nojiri T, Kobayashi T, Masuda A, Ikeda H, Nagamatsu T, Fujii T, Aoki J, Yatomi Y. A New Enzyme Immunoassay for the Quantitative Determination of Classical Autotaxins (ATXalpha, ATXbeta, and ATXgamma) and Nove — View Citation
Tsuchida Y, Shoda H, Nakano M, Ota M, Okamura T, Yamamoto K, Kurano M, Yatomi Y, Fujio K, Sawada T. Autotaxin is a potential link between genetic risk factors and immunological disturbances of plasmacytoid dendritic cells in systematic lupus erythematosus — View Citation
Tsuchida Y, Shoda H, Sawada T, Fujio K. Role of autotaxin in systemic lupus erythematosus. Front Med (Lausanne). 2023 Apr 4;10:1166343. doi: 10.3389/fmed.2023.1166343. eCollection 2023. — View Citation
Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021 Jun 22;11(7):928. doi: 10.3390/biom11070928. — View Citation
Zhang G, Cheng Y, Zhang Q, Li X, Zhou J, Wang J, Wei L. ATX-LPA axis facilitates estrogen-induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway. Mol Med Rep. 2018 Mar;17(3):4245-4252. doi: 10.3892/mmr.2018.8392. Epub 2018 Jan 8. — View Citation
* Note: There are 13 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum ATX level in SLE patients in comparison to healthy controls. | Measure ATX level in serum of sle patients and compare it with ATX level in serum of healthy controls. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05624437 -
BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus
|
||
Recruiting |
NCT06445127 -
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
|
N/A | |
Recruiting |
NCT04866615 -
Posterior Segment Evaluation of Patients With SLE Using OCT and OCTA
|
||
Not yet recruiting |
NCT04645225 -
Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus
|
||
Recruiting |
NCT04604990 -
National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia
|
||
Recruiting |
NCT06150651 -
Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.
|
Phase 1 | |
Recruiting |
NCT06056921 -
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
|
Phase 1 | |
Recruiting |
NCT06294236 -
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
|
Phase 1 | |
Recruiting |
NCT05866861 -
A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus
|
Phase 1 |